June 14, 2017 Combination of TGR-1202 (umbralisib) plus ibrutinib appears well tolerated with no Grade 3/4 transaminitis, pneumonitis, diarrhea, or colitis observed, with longest patients on study 29.5+ months 94% of the CLL patients achieved a CR, PR or PR-L, including 1 patient with a CR, and 3 additional patients with radiographic CR`s 79% ORR in patients with MCL, including 1 patient with a CR and 1 additional patient with a radiographic CR NEW YORK, June 14, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced updated clinical data from its ongoing Phase I/Ib trial of TGR-1202 (umbralisib), the Company`s oral, next generation PI3K delta inhibitor, in combination...
|
